deferoxamine has been researched along with Emesis in 7 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of ferric chloride and deferoxamine, an iron chelator, on cisplatin-induced emesis were studied in Suncus murinus." | 7.68 | Effects of iron and deferoxamine on cisplatin-induced emesis: further evidence for the role of free radicals. ( Matsuki, N; Saito, H; Torii, Y, 1993) |
| "To determine whether leukocytosis, hyperglycemia, vomiting, and opacities in abdominal radiographs are indicators of a serum iron concentration of > 300 micrograms/dL in adult iron overdose patients, a retrospective medical record review was undertaken at a university medical center of all patients older than 12 years of age for whom clinical data were collected before deferoxamine therapy and within 6 hours of iron ingestion." | 3.69 | Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults. ( Palatnick, W; Tenenbein, M, 1996) |
| "The effects of ferric chloride and deferoxamine, an iron chelator, on cisplatin-induced emesis were studied in Suncus murinus." | 3.68 | Effects of iron and deferoxamine on cisplatin-induced emesis: further evidence for the role of free radicals. ( Matsuki, N; Saito, H; Torii, Y, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuki, N | 1 |
| Torii, Y | 1 |
| Saito, H | 1 |
| Palatnick, W | 1 |
| Tenenbein, M | 1 |
| Haddad, LM | 1 |
| Banner, W | 1 |
| Tong, TG | 1 |
| Robertson, WO | 1 |
| Westlin, WF | 1 |
| Hosking, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911] | Phase 3 | 120 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 15 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 17 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Aprepitant Regimen | 15 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）" (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 18 |
| Control Regimen | 15 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 7 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 6 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 41 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 35 |
| Control Regimen | 40 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 31 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 30 |
2 reviews available for deferoxamine and Emesis
| Article | Year |
|---|---|
Iron poisoning.
Topics: Absorption; Bicarbonates; Chemical and Drug Induced Liver Injury; Child, Preschool; Deferoxamine; Di | 1986 |
Treatment of acute iron poisoning.
Topics: Acidosis; Acute Disease; Bicarbonates; Deferoxamine; Diarrhea; Edetic Acid; Emetics; Humans; Infusio | 1971 |
5 other studies available for deferoxamine and Emesis
| Article | Year |
|---|---|
Effects of iron and deferoxamine on cisplatin-induced emesis: further evidence for the role of free radicals.
Topics: Animals; Chlorides; Cisplatin; Deferoxamine; Drug Synergism; Female; Ferric Compounds; Free Radicals | 1993 |
Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults.
Topics: Adolescent; Adult; Blood Glucose; Deferoxamine; Drug Overdose; Female; Humans; Hyperglycemia; Iron; | 1996 |
Iron poisoning.
Topics: Child; Deferoxamine; Gastric Lavage; Humans; Ipecac; Iron; Vomiting | 1976 |
Deferoxamine as a chelating agent.
Topics: Chelating Agents; Chemical Phenomena; Chemistry; Child; Deferoxamine; Diarrhea; Female; Humans; Hypo | 1971 |
Radiology in the management of acute iron poisoning.
Topics: Acute Disease; Deferoxamine; Diagnosis, Differential; Gastric Lavage; Humans; Infant; Iron; Lung; Ma | 1969 |